StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research report sent to investors on Wednesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
Several other analysts have also weighed in on the stock. Alliance Global Partners reiterated a neutral rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Maxim Group reaffirmed a hold rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Finally, HC Wainwright cut shares of Alimera Sciences from a buy rating to a neutral rating and set a $6.00 price objective on the stock. in a research report on Tuesday, June 25th.
Read Our Latest Stock Analysis on Alimera Sciences
Alimera Sciences Stock Performance
Alimera Sciences (NASDAQ:ALIM – Get Free Report) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The business had revenue of $27.00 million for the quarter, compared to the consensus estimate of $25.76 million. Alimera Sciences had a negative net margin of 23.74% and a negative return on equity of 53.49%. As a group, analysts predict that Alimera Sciences will post -0.13 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Glazer Capital LLC bought a new position in Alimera Sciences in the 2nd quarter valued at about $3,067,000. Gabelli Funds LLC purchased a new position in shares of Alimera Sciences during the second quarter valued at approximately $600,000. Renaissance Technologies LLC grew its holdings in Alimera Sciences by 3.9% during the second quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock worth $1,010,000 after buying an additional 6,900 shares in the last quarter. Rhumbline Advisers purchased a new stake in Alimera Sciences in the 2nd quarter valued at $113,000. Finally, Bank of New York Mellon Corp bought a new position in Alimera Sciences during the 2nd quarter valued at $344,000. Institutional investors and hedge funds own 99.83% of the company’s stock.
Alimera Sciences Company Profile
Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Further Reading
- Five stocks we like better than Alimera Sciences
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- Comparing and Trading High PE Ratio Stocks
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.